MARIMED INC.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
MRMDStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common stock · Additional paid-in capital · Accumulated deficit · Non-controlling interests · Total stockholders' equity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Par Value | |||||||||||
| Balances at January 1, 2024 | 375,126,352 | $375 | $171,144 | $(100,981) | $(1,650) | $68,888 | |||||
| Release of shares under stock grants | 2,636,750 | 2 | (2) | — | — | — | |||||
| Shares of newly vested common stock surrendered to the Company to satisfy tax withholding obligations | (249,087) | — | (41) | — | — | (41) | |||||
| Standalone warrants issue as payment for services | — | — | 218 | — | — | 218 | |||||
| Common stock issued under a licensing and royalty agreement | 45,299 | — | 10 | — | — | 10 | |||||
| Common stock issued as purchase consideration - business acquisition | 3,917,267 | 4 | 987 | — | — | 991 | |||||
| Distributions to noncontrolling interests | — | — | — | — | (139) | (139) | |||||
| Stock-based compensation | — | — | 1,050 | — | — | 1,050 | |||||
| Net (loss) income | — | — | — | (12,467) | 37 | (12,430) | |||||
| Balances at December 31, 2024 | 381,476,581 | $381 | $173,366 | $(113,448) | $(1,752) | $58,547 | |||||
| Release of shares under stock grants | 10,432,811 | 10 | (10) | — | — | — | |||||
| Shares of newly vested common stock surrendered to the Company to satisfy tax withholding obligations | (801,143) | — | (83) | — | — | (83) | |||||
| Conversion of preferred stock to common stock | 5,776,370 | 6 | 4,269 | — | — | 4,275 | |||||
| Common stock issued under a licensing and royalty agreement | 26,749 | — | 3 | — | — | 3 | |||||
| Distributions to noncontrolling interests | — | — | — | — | (137) | (137) | |||||
| Stock-based compensation | — | — | 1,860 | — | — | 1,860 | |||||
| Net (loss) income | — | — | — | (14,484) | 28 | (14,456) | |||||
| Balances at December 31, 2025 | 396,911,368 | $397 | $179,405 | $(127,932) | $(1,861) | $50,009 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.